Back to Search
Start Over
Immunogenicity of an AS01-adjuvanted respiratory syncytial virus prefusion F (RSVPreF3) vaccine in animal models.
- Source :
- NPJ Vaccines; 11/20/2023, Vol. 8 Issue 1, p1-10, 10p
- Publication Year :
- 2023
-
Abstract
- Respiratory syncytial virus (RSV) causes a high disease burden in older adults. An effective vaccine for this RSV-primed population may need to boost/elicit robust RSV-neutralizing antibody responses and recall/induce RSV-specific T cell responses. To inform the selection of the vaccine formulation for older adults, RSVPreF3 (RSV fusion glycoprotein engineered to maintain the prefusion conformation) with/without AS01 adjuvant was evaluated in mice and bovine RSV infection-primed cattle. In mice, RSVPreF3/AS01 elicited robust RSV-A/B-specific neutralization titers and RSV F-specific polyfunctional CD4<superscript>+</superscript> T cell responses exceeding those induced by non-adjuvanted RSVPreF3. In primed bovines, RSVPreF3/AS01 tended to induce higher pre-/post-vaccination fold-increases in RSV-A/B-specific neutralization titers relative to non-adjuvanted and Alum-adjuvanted RSVPreF3 formulations, and elicited higher RSV F-specific CD4<superscript>+</superscript> T cell frequencies relative to the non-adjuvanted vaccine. Though AS01 adjuvanticity varied by animal species and priming status, RSVPreF3/AS01 elicited/boosted RSV-A/B-specific neutralization titers and RSV F-specific CD4<superscript>+</superscript> T cell responses in both animal models, which supported its further clinical evaluation as prophylactic candidate vaccine for older adults. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 20590105
- Volume :
- 8
- Issue :
- 1
- Database :
- Complementary Index
- Journal :
- NPJ Vaccines
- Publication Type :
- Academic Journal
- Accession number :
- 173766888
- Full Text :
- https://doi.org/10.1038/s41541-023-00729-4